Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Ticiana A. Leal"'
Autor:
Ticiana A. Leal, Anandaroop Dasgupta, Dominick Latremouille-Viau, Carmine Rossi, Pragya Rai, Fabrice Barlesi, Stephen V. Liu
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
PURPOSETo characterize treatment patterns and real-world clinical outcomes of patients with metastatic non–small cell lung cancer (mNSCLC) who developed progression on an anti–PD-1/anti–PD-L1, herein referred to as anti–PD-(L)1, and platinum-
Externí odkaz:
https://doaj.org/article/e6b4ccf222ad461c9444021a76527e9e
Autor:
Ticiana A. Leal, Marina N. Sharifi, Nancy Chan, Robert Wesolowski, Anita A. Turk, Justine Y. Bruce, Ruth M. O'Regan, Jens Eickhoff, Lisa M. Barroilhet, Jyoti Malhotra, Janice Mehnert, Eugenia Girda, Elizabeth Wiley, Natalie Schmitz, Shannon Andrews, Glenn Liu, Kari B. Wisinski
Publikováno v:
Cancer Medicine, Vol 11, Iss 21, Pp 3969-3981 (2022)
Abstract Background Inhibitors of poly(ADP‐ribose) polymerase (PARP) proteins potentiate antitumor activity of platinum chemotherapy. This study sought to determine the safety and tolerability of PARP inhibitor talazoparib with carboplatin and pacl
Externí odkaz:
https://doaj.org/article/d110893465fc4eceb9dd0c7b44d3c53f
Autor:
Jennifer L. Schehr, Nan Sethakorn, Zachery D. Schultz, Camila I. Hernandez, Rory M. Bade, Diego Eyzaguirre, Anupama Singh, David J. Niles, Leslie Henderson, Jay W. Warrick, Scott M. Berry, Kaitlin E. Sundling, David J. Beebe, Ticiana A. Leal, Joshua M. Lang
Publikováno v:
Biomarker Research, Vol 10, Iss 1, Pp 1-13 (2022)
Abstract Introduction PD-L1 expression in non-small cell lung cancer (NSCLC) predicts response to immune checkpoint blockade, however is an imperfect biomarker given tumor heterogeneity, and the antigen presentation pathway requiring other components
Externí odkaz:
https://doaj.org/article/b9045af0a9af4371a592c3d1c272ffac
Autor:
Laurie E. Steffen McLouth, Fengmin Zhao, Taofeek K. Owonikoko, Josephine L. Feliciano, Nisha A. Mohindra, Suzanne E. Dahlberg, James L. Wade III, Gordan Srkalovic, Bradley W. Lash, Joseph W. Leach, Ticiana A. Leal, Charu Aggarwal, David Cella, Suresh S. Ramalingam, Lynne I. Wagner
Publikováno v:
Cancer Medicine, Vol 9, Iss 20, Pp 7511-7523 (2020)
Abstract Objectives The ECOG‐ACRIN Cancer Research Group trial E2511 recently demonstrated a potential benefit for the addition of veliparib to cisplatin‐etoposide (CE) in patients with extensive stage small cell lung cancer (ES‐SCLC) in a phas
Externí odkaz:
https://doaj.org/article/50292329a4084b0f8f95400fae2f2d06
Publikováno v:
Cancer. 129:1319-1350
Autor:
Sai-Hong Ignatius Ou, Pasi A. Jänne, Ticiana A. Leal, Igor I. Rybkin, Joshua K. Sabari, Minal A. Barve, Lyudmila Bazhenova, Melissa L. Johnson, Karen L. Velastegui, Cornelius Cilliers, James G. Christensen, Xiaohong Yan, Richard C. Chao, Kyriakos P. Papadopoulos
Publikováno v:
Journal of Clinical Oncology. 40:2530-2538
PURPOSE Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRASG12C. We report results from a phase I/IB study of adagrasib in non–small-cell lung cancer, colorectal cancer, and other solid tumors harboring the
Autor:
Randall J. Kimple, Shuang G. Zhao, Ticiana A. Leal, Kwangok P. Nickel, Colin A. Longhurst, Paul A. Clark, Lindsey Abel, Saakshi Kaushik, Justin H. Skiba, Ashley C. Kromke, Haley J. VanBeek, Jacob H. Elnaggar, Andrew M. Baschnagel
M6620, a selective ATP-competitive inhibitor of the ATM and RAD3-related (ATR) kinase, is currently under investigation with radiation in patients with non–small cell lung cancer (NSCLC) brain metastases. We evaluated the DNA damage response (DDR)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1022828dcc5353716a90d96a2e4e7f69
https://doi.org/10.1158/1535-7163.c.6543216
https://doi.org/10.1158/1535-7163.c.6543216
Autor:
Randall J. Kimple, Shuang G. Zhao, Ticiana A. Leal, Kwangok P. Nickel, Colin A. Longhurst, Paul A. Clark, Lindsey Abel, Saakshi Kaushik, Justin H. Skiba, Ashley C. Kromke, Haley J. VanBeek, Jacob H. Elnaggar, Andrew M. Baschnagel
Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ef8d8e3df2d81fc342a831aff1366d3
https://doi.org/10.1158/1535-7163.22521897
https://doi.org/10.1158/1535-7163.22521897
Autor:
Heather A. Wakelee, Christine M. Lovly, Allison Holzhausen, James J. Gibbons, Chris Liang, Kimberly Harrow, Gary Dukart, Jon P. Gockerman, Joel W. Neal, Liping Du, Jennifer G. Whisenant, Rachel E. Sanborn, Barbara J. Gitlitz, Saiama N. Waqar, Ticiana A. Leal, George R. Blumenschein, Karen L. Reckamp, Jeffrey R. Infante, Leora Horn
Supplemental Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54b6a5679d59d795489c267075719ba7
https://doi.org/10.1158/1078-0432.22464939
https://doi.org/10.1158/1078-0432.22464939
Autor:
Heather A. Wakelee, Christine M. Lovly, Allison Holzhausen, James J. Gibbons, Chris Liang, Kimberly Harrow, Gary Dukart, Jon P. Gockerman, Joel W. Neal, Liping Du, Jennifer G. Whisenant, Rachel E. Sanborn, Barbara J. Gitlitz, Saiama N. Waqar, Ticiana A. Leal, George R. Blumenschein, Karen L. Reckamp, Jeffrey R. Infante, Leora Horn
Supplemental Figure 1. Representative example from one patient showing the rash that was most frequently observed with ensartinib. The white arrow in the top figure points to the rash that is circled in the bottom figure.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f66975726db644fb04183f8f0be7ce6
https://doi.org/10.1158/1078-0432.22464948
https://doi.org/10.1158/1078-0432.22464948